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We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo
Philadelphia chromosome-positive (Phþ) acute lymphoblastic leukemia (ALL). Imatinib-based strategy
improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P ¼ .0001).
Despite the selection in patients who actually underwent transplantation, these results suggest that alloge-
neic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Phþ ALL
in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without
a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55
years, including 7 patients in complete molecular response).
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION approximately 75% [4-9]. However, to date, there is no
Philadelphia chromosome positive (Phþ) is the most
frequent recurrent cytogenetic abnormality observed in
adult patients diagnosed with acute lymphoblastic leukemia
(ALL). Before the tyrosine kinase inhibitor (TKI) era, the
outcome of patients with Phþ ALL was very poor, with long-
term survival rates, at best, reaching 20% in most studies
[1,2]. Allogeneic stem cell transplant (SCT) has been consid-
ered as the consolidation treatment of choice once achieving
a ﬁrst complete remission (CR), as it provides the best
outcome in this setting [3]. In recent years, the most signif-
icant advance in term of treatment has been the introduction
of TKIs into Phþ ALL treatment protocols. Several groups
have shown that the combination of concurrent or alter-
nating use of imatinib with high-dose chemotherapy has
signiﬁcantly improved the outcome of adults and children
with newly diagnosed Phþ ALL, with higher CR rates (nearly
95%) and 12-month overall survival (OS) reachingedgments on page 155.
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12.08.021evidence that TKIs may impact on the long-term outcome of
patients with Phþ ALL, because the follow-up of published
studies did not exceed 2 years [4-10]. In a ﬁrst analysis of the
GRAAPH-2003 study, CR rate, 18-month disease-free survival
(DFS), and OS were 96%, 51%, and 65%, respectively [11]. In
the present analysis, results of the GRAAPH-2003 study have
been actualized with a longer median follow-up reaching
3.86 years.PATIENTS AND METHODS
From January 2004 to October 2005, 45 patients with newly diagnosed
de novo Phþ ALL (median age, 45 years; range,16-59 years) were included in
the GRAAPH-2003 study. The Phþ was detected by standard karyotype
and/or ﬂuorescence in situ hybridization analysis and/or BCR-ABL fusion
transcript detection by reverse transcription-PCR. Patients with previous
chronic myeloid leukemia or myeloproliferative disorders were excluded.
All patients gave their written informed consent before the study. The study
was approved in March 2003 by the institutional review board of Hôpital
Purpan, Toulouse, France, and conducted in accordancewith the Declaration
of Helsinki. Details regarding this study have been published elsewhere [11].
The protocol schedule is summarized in Figure 1. Following a 7-day
prednisone pre-phase, corticosteroid sensitivity (CS) was assessed by
peripheral blood examination and was deﬁned as <1.0  109/L residual
circulating blasts. Chemotherapy sensitivity (ChS) was assessed by periph-
eral blood and bone marrow (BM) examination 8 days after the start of an
induction chemotherapy including daunorubicin, cyclophosphamide,Transplantation.
Figure 1. Treatment and patient ﬂow chart.
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of circulating blasts and <5% of marrow blasts. Treatment strategy was
stratiﬁed according to CS and ChS. Patients with a disease deﬁned as cortico-
sensitive and chemo-sensitive (good early responders) received a standard
induction. Subsequently, patients achieving hematological CR received
imatinib (600 mg per day) combined with consolidation chemotherapy
including mitoxantrone and cytarabine. Imatinib was given from day 1 of
the consolidation course to SCT. Patients with cortico-resistant or chemo-
resistant disease (poor early responders) received, either by day 8 (if
cortico-resistant) or day 15 (if chemo-resistant), high-dose imatinib (800mg
per day) combined with vincristine and dexamethasone as the second part
of the induction regimen (DIV combination), and subsequently, imatinib
alone until SCT.
All patients in hematological CR, age <56 years, with either an HLA-
identical sibling donor or an HLA-matched unrelated donor (matched at 9
or 10 of 10 HLA antigens) were eligible for allogeneic SCT. For SCT, the
preparative regimen included high-dose cyclophosphamide (120 mg/kg
total dose, 60 mg/kg/day i.v. for 2 consecutive days) and total body irradi-
ation (12 Gy total dose in 6 fractions for 3 days). Graft-versus-host disease
prophylaxis associated methotrexate (15 mg/m2 at day þ1, 10 mg/m2 at
day þ3, day þ6, and day þ11) and cyclosporine (3 mg/kg per day by
continuous i.v. infusion started at day 1, then switched orally, with adap-
tations according to blood concentration and tapered by day þ60). No
imatinib maintenance therapy was planned after transplantation, either
autologous or allogeneic.
Marrow minimal residual disease (MRD) was monitored using reverse
transcription-PCR, centralized in predeﬁned reference laboratories.
According to a minimum sensitivity level of 105, low BCR-ABL level was
deﬁned as no BCR-ABL transcript detection or as a BCR-ABL/ABL ratio
between 105 and 104.
Patients with a BM MRD ratio <104, but without any donor or >55
years, were eligible for autologous SCT. Patients who failed to achieve this
BM MRD level were further treated with imatinib combined with various
chemotherapy regimens.
Results of the GRAAPH-2003 study were compared to those obtained by
the pre-imatinib French trial, LALA-94 [2], which included 154 patients with
de novo Phþ ALL between 1994 and 2000, and used standard induction
chemotherapy combining prednisone, vincristine, and cyclophosphamide
with an anthracycline (daunorubicin or idarubicin) followed by a consoli-
dation course combining mitoxantrone with intermediate-dose cytarabine
(HAM). All of the 103 patients in hematological CR after these 2 chemo-
therapy courses underwent allogeneic SCT if a matched donor was identi-
ﬁed, or autologous SCT if not.Table 1
Patient Characteristics According to the Type of Consolidation Therapy
Covariates Allogeneic SCT Allogene
Sibling Donor Unrelate
N ¼ 15 N ¼ 9
Age at diagnosis
Median (years) 40 40
Range (years) 20-55 16-56
Gender
Female 5 5
Male 10 4
WBC at diagnosis
Median, range (G/L) 26 22
Range (G/L) 2-143 1-159
WBC  50 G/L 4 2
Cytogenetics
Complex karyotypes 4 3
Other karyotypes 8 6
Missing/failure 3 0
Early response
CS and ChS 9 7
Other proﬁles 6 2
MRD1 level
Median 0.00003 0.0000
Range 0-0.026 0-0.05
High 6 2
Low 4 4
Negative 5 3
MRD2 level
Median 0.0017 0.0000
Range 0-0.026 0-0.05
SCT indicates stem cell transplant; CS, corticosteroid sensitivity; ChS, chemotherapStatistical Analysis
An update of the database was performed by May 18, 2012. At this time
point, the median follow-up was 2.46 years for the overall group of patients
(range, 0.05-4.98 years) and 3.86 years for those alive at the last follow-up
evaluation (range, 0.9-4.98 years). All analyses were conducted according
to the intention-to-treat principle. DFS was measured from the time of ﬁrst
CR to the date of relapse or death, whatever the cause. Relapse was deﬁned
as leukemia recurrence after ﬁrst CR. OS was deﬁned as the time interval
from randomization until death, whatever the cause. The probabilities of
DFS and OS were estimated according to the Kaplan-Meier product limit
method and compared using either the 2-tailed log-rank test or Cox
proportional hazards regression analysis. Departure from the proportional
hazards assumption was assessed using methods based on partial residuals
and a graphical approach. Competing risks analysis and the Gray test were
used to calculate and compare the cumulative incidence of treatment-
related death and relapse between groups. The Fine and Gray model was
used to estimate relative risks (RRs) and 95% conﬁdence intervals (CIs) for
competing risks analyses. According to group size, chi-square analysis or
Fisher exact test was used to compare categorical covariates. The Mann-
Whitney U test was used to compare medians. All statistical analyses were
conducted with S-Plus 8.0 for Windows Enterprise Developer (Insightful
Corporation, Seattle, WA).
RESULTS
As previously reported [11], the CR rate after the induc-
tion phase was 96%. First CR was achieved in 14 patients
(31%) after mitoxantrone, intermediate dose cytarabine, and
imatinib, and 29 patients (64%) after DIV (Figure 1). Two
patients died during DIV chemotherapy. Twenty-four of the
43 patients in CR received allogeneic SCT from either an HLA-
identical sibling donor (n¼ 15) or an HLA-matched unrelated
donor (n¼ 8), or from an unrelated cord blood donor (n¼ 1).
Nineteen patients in CR did not receive allogeneic SCT
because they were >55 years (n ¼ 4) or had no available or
identiﬁed donor (n ¼ 15). Among them, 10 received intensi-
ﬁcation therapy followed by autologous SCT. Seven patients
achieved at least a low MRD level before undergoing the
transplantation procedure, whereas 3 patients had positive
pretransplantation MRD. Although no maintenance therapyic SCT Autologous SCT Chemotherapy
d Donor
N ¼ 10 N ¼ 9
44 50
27-59 42-55
6 4
4 5
8 12
2-151 7-78
1 1
1 1
9 8
0 0
7 6
3 3
2 0.000045 0.00005
0-0.02 0-0.001
3 4
4 3
3 2
2 0.00053 0.00005
0-0.02 0-0.001
y sensitivity; MRD, minimal residual disease.
Table 2
Four-Year OS and DFS of the GRAAPH-2003 and LALA-94 Trials
OS 4-Years Estimated, % (95% CI) DFS 4-Years Estimated, % (95% CI) CIR % (95% CI) TRM of Patients in CR %
LALA-94 (103 patients in CR) *20 (14-26) *20 (14-28) 42 (34-50) 16
GRAAPH-2003 (43 patients in CR) 52 (36-66) *P ¼ .0001 43 (27-58) *P ¼ .002 24 (14-40) 11
OS indicates overall survival; DFS, disease-free survival; CI, conﬁdence interval; CIR, cumulative incidence of relapse; CR, complete remission; TRM, treatment-
related mortality; *, P.
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Furthermore, 9 patients received an “off protocol” mainte-
nance chemotherapy with imatinib because they failed to
achieve a low MRD level (n ¼ 4) or because investigators
waited for the identiﬁcation of an HLA-matched unrelated
donor before to resolve to perform autologous SCT (Table 1).
For the entire cohort, the 4-year OS and DFS were 52%
(95% CI, 39%-70%) and 44% (95% CI, 31%-62%), respectively
(Figure S1A and B, online only). A highly signiﬁcant
improvement of the outcome was observed when compared
to the LALA-94 trial (Table 2). The 4-year cumulative inci-
dence rates of relapse and treatment-relatedmortality (TRM)
were 36% (95% CI, 21%-51%) and 21% (95% CI, 8%-34%),
respectively. In univariate analysis, WBC count at the time of
diagnosis was the only covariate affecting signiﬁcantly
relapse incidence and DFS (Figure S1C and D, online only)
(when considering the logarithm of the WBC count at diag-
nosis, i.e., leukocytosis as a continuous covariate: RR for the
4-year DFS, 1.45; 95% CI, 1.03-2.05; P ¼ .034; RR for the
4-year relapse incidence, 1.61; 95% CI, 1.06-2.45; P ¼ .027).
Table 3 summarizes the 43 remitters, the 4-year cumu-
lative incidence of relapse, the 4-year TRM rate, the 4-year
OS, and the 4-year DFS (Figure S2A and B, online only)
according to the type of consolidation treatment (allogeneicTable 3
Outcome of the Patients According to the Type of Consolidation Therapy and
the MRD Level after the Induction Phase
Covariates 4-Year OS 4-Year DFS 4-Year REL 4-Year TRM
Allogeneic
SCT sibling (1)
76% 71% 27% 7%
95% CI 56%-100% 51%-100% 4%-50% 0%-20%
Allogeneic
SCT URD (2)
11% 11% 44% 44%
95% CI 2%-70% 2%-70% 8%-80% 6%-82%
Autologous SCT (3) 80% 50% 50% 0%
95% CI 59%-100% 27%-93% 17%-83% –
No SCT (4) 33% 33% 39% 28%
95% CI 11%-98% 11%-98% 0%-81% 0%-66%
High MRD level 51% 29% 71% 0%
95% CI 29%-89% 12%-73% 41%-100% –
Low MRD level 51% 47% 40% 13%
95% CI 31%-85% 27%-80% 14%-66% 0%-31%
Negative MRD level 61% 54% 8% 38%
95% CI 39%-95% 33%-89% 0%-23% 10%-66%
P values
(1) versus (2) .003 .009 .40 .042
(1) versus (3) .44 .79 .23 .41
(1) versus (4) .17 .026 .54 .24
(2) versus (3) .09 .0007 .88 .024
(2) versus (4) .45 .52 .85 .52
(3) versus (4) .47 .024 .74 .09
High versus low
MRD level
0.52 0.89 0.34 0.15
High versus negative
MRD level
0.98 0.26 0.002 0.016
Low versus negative
MRD level
0.58 0.38 0.041 0.19
MRD indicates minimal residual disease; OS, overall survival; DFS, disease-
free survival; REL, relapse; TRM, treatment-related mortality; SCT, stem cell
transplant; CI, conﬁdence interval; URD, unrelated donor.SCT versus autologous SCT versus chemotherapy alone). The
only signiﬁcant difference was observed in terms of OS
between patients who received autologous SCT and those
who did not undergo transplantation.
Regarding the outcome of the 24 patients who received
allogeneic SCT, a signiﬁcant difference was observed accord-
ing to the type of donor (HLA-identical sibling versus unre-
lated donor) in terms of OS, DFS, and TRM (Table 3 - Figure 2).
The best results were observed in patients who underwent
transplantation fromanHLA-identical sibling donor,whereas
those who underwent transplantation from an unrelated
donor presented a higher TRM rate (1-year TRM, 22%; 95% CI,
0%-51% versus 7%; 95% CI, 0%-20%), without any gain in terms
of relapse incidence. Patients undergoing autologous SCT had
a similar 4-year OS than those receiving allogeneic SCT from
an HLA-identical sibling donor. The higher relapse incidence
observed in patients who received autologous SCT was
balanced by a lower TRM rate.
Table 3 also shows outcome according to the MRD level
achieved after the induction phase. There were no statisti-
cally signiﬁcant differences in terms of survival between
patients with high, low, or negative MRD levels after the
induction phase (Figure S3, online only). Similar results were
observed when considering the MRD level as a continuous
variable. For the entire cohort, relapse incidence decreased
concomitantly to MRD level (Figure 3). TRM was inversely
correlated to the relapse incidence, and higher TRM rates
were correlated to negative MRD levels (Figure 3). Similar
results were observed when only considering patients who
received allogeneic SCT (data not shown).
DISCUSSION
This updated analysis of the GRAAPH-2003 trial conﬁrms
and extends the previously published results [11]. Results are
in agreement with those from other reports suggesting that,
in patients with Phþ ALL, the addition of imatinib to ﬁrst-line
chemotherapy is associated with an improved long-term
outcome [12-14].
Our results suggest that even when including imatinib
during the induction phase, the prognosis of patients can
again be improved by intensifying the postremission phase,
through either autologous SCT (especially if a low or negative
MRD level is achieved after the induction phase) or alloge-
neic SCT, especially from an HLA-identical sibling. In both
“optimized situations,” the 4-year OS was above 75% (4-year
OS, 76%; 95% CI, 56%-100% with allogeneic SCT from an HLA-
identical sibling (4-year OS, 86%; 95% CI, 63%-100% with
autologous SCT and MRD low or negative), and the 4-year
DFS above 70% (4-year DFS, 71%; 95% CI, 51%-100% with
allogeneic SCT from an HLA-identical sibling (4-year DFS,
78%; 95% CI, 55%-100% with autologous SCT and MRD low or
negative). Results of autologous SCT were encouraging with
no TRM and a relapse incidence not statistically different
from that observed after allogeneic SCT. These results might
be explained by the fact that imatinib administration was
stratiﬁed according to the MRD level assessed after the
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Figure 2. Four-year overall survival (OS) and disease-free survival (DFS) of the 43 patients who achieved complete remission (CR) in the GRAAPH-2003 study
according to the consolidation treatment. (A) The 4-year OS was 76% (95% conﬁdence interval [CI], 56%-100%) for those who received allogeneic stem cell transplant
(SCT) from an HLA-identical sibling donor (black curve), 11% (95% CI, 2%-70%) for those who received allogeneic SCT from an unrelated donor (blue curve), 80% (95% CI,
59%-100%) for those who received autologous SCT (red curve), and 33% (95% CI, 11%-98%) for those who did not undergo transplantation (green curve) (P value [log-
rank test] < .0003). (B) The 4-year DFS was 71% (95% CI, 51%-100%) for those who received allogeneic SCT from an HLA-identical sibling donor (black curve), 11% (95%
CI, 2%-70%) for those who received allogeneic SCT from an unrelated donor (blue curve), 50% (95% CI, 27%-93%) for those who received autologous SCT (red curve), and
33% (95% CI, 11%-98%) for those who did not undergo transplantation (green curve) (P value [log-rank test] ¼ .07).
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administration in previous studies [13,14]. Therefore, most of
the patients who underwent autologous SCT were good early
responders. The 3 patients who received autologous SCT,
despite a positive pretransplantation MRD evaluation,
relapsed (at 1, 4, and 18 months posttransplantation,
respectively). Although not planned in the protocol, 4
patients received imatinib as maintenance therapy after
autologous SCT, which could have inﬂuenced the outcome of
this group of patients. Among them, 3 patients were still
alive in ﬁrst CR at 37, 41, and 46 months posttransplantation,
and 1 patient who has relapsed after 1 month remained alive
at 48 months posttransplantation. Finally, although not
statistically signiﬁcant, lower WBC counts at diagnosis were
observed in patients who received autologous SCT0 1 2 3 4
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Figure 3. Four-year relapse incidence and treatment-related mortality (TRM)
of the 43 patients who achieved complete remission (CR) in the GRAAPH-2003
study according to the minimal residual disease (MRD) level after the induc-
tion phase. The 4-year relapse incidence was 8% (95% conﬁdence interval [CI],
0%-23%) for those who had a negative MRD evaluation (red curve), 40% (95%
CI, 14%-66%) for those who had a low MRD level evaluation (dark blue curve),
and 71% (95% CI, 41%-100%) for those who had a high MRD level evaluation
(black curve) (P value [Gray test] < .014). The 4-year TRM was 38% (95% CI, 10-
66%) for those who had a negative MRD evaluation (light blue curve), 13% (95%
CI, 0-31%) for those who had a low MRD level evaluation (orange curve), and
0% for those who had a high MRD level evaluation (green curve) (P value [Gray
test] ¼ .038).comparatively to those observed in patients who received an
allogeneic SCT group from an HLA-identical sibling donor
(median leukocytosis: 8 G/L versus 26 G/L, respectively). This
covariate was the only one associated with 2 of the main
endpoints for the entire cohort: the 4-year DFS and the
relapse incidence. Only 1 patient with a WBC count above 50
G/L received autologous SCT. He rapidly relapsed despite the
achievement of a low MRD level after the induction phase.
Our results, although based on a limited number of
patients, suggest that the autologous SCT option should be
reconsidered in the imatinib era for Phþ ALL patients with
a low or negative MRD level after the induction phase. In our
previous LALA-94 trial [2], we reported a favorable prog-
nostic value when molecular remission was obtained after 2
chemotherapy courses independently of the presence of
a donor. Molecular response was therefore considered as
a good surrogate endpoint of the disease, and autologous SCT
was avoided in patients with persistent MRD. The potential
role of imatinib, as maintenance therapy after SCT in order to
further reduce relapse incidence, remains an important issue
that should be addressed prospectively. Radich et al. [15], in
a retrospective series of 36 patients with Phþ ALL who
underwent transplantation at the Fred Hutchinson Cancer
Research Center, and subsequently Stirewalt et al. [16],
analyzing the outcome of 90 patients with Phþ ALL who
underwent transplantation at the same center, showed that
the persistent expression of BCR-ABL during the ﬁrst 100
days posttransplantation was associated with a higher inci-
dence of relapse and a lower DFS. Both studies argue in favor
of a maintenance therapy with imatinib after transplantation
in patients with a positive MRD evaluation, especially when
no chronic graft-versus-host immune reaction can be
expected.
Unexpectedly, early MRD evaluation did not signiﬁcantly
inﬂuence patient outcome, both in terms of OS and DFS. The
beneﬁt of a low or negative MRD level, which translated into
a signiﬁcant lower incidence of relapse, was almost
completely abrogated by the fact that these patients
A. Tanguy-Schmidt et al. / Biol Blood Marrow Transplant 19 (2013) 150e155 155experienced the highest TRM rate. This was observed mainly
for patients who received allogeneic SCT, and especially for
those who underwent transplantation with an unrelated
donor. In this group, a particularly poor outcome was
observed with a 4-year TRM greater than 40% and a 4-year
OS and DFS of only 11%. Combined with the relatively
advanced age of patients with Phþ ALL and the high proba-
bility of graft-versus-leukemia effect in this disease [17],
these results tend to argue in favor of allogeneic SCT after
reduced-intensity conditioning for adult patients with Phþ
ALL when no HLA-identical sibling donor is available.
Whether autologous SCT with a low or negative MRD level
should be performed instead of allogeneic SCT using an HLA-
matched unrelated donor in patients with Phþ ALL is a crit-
ical issue that should further be addressed through
a prospective controlled study.ACKNOWLEDGMENTS
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